trim outlook account increment
guidanc still upsid consensu
last week investor confer reiter financi guidanc
provid increment comment suggest pronounc season
previous forecast specif expect account roughli
full year compar prior year prior forecast equat
test access revenu trim
revenu outlook test access
full-year forecast revenu goe
test access goe ep goe
due lower revenu manag guidanc unchang test
access revenu maintain outperform
bullish revenu test volum lower
revenu outlook street-high continu see upsid
manag guidanc street consensu base market
share gain hereditari cancer insur reimburs channel driven
part roll-out unit pln believ test volum guidanc requir
meaning contribut nip patient-initi test
carri lower-than-averag disproportion small impact
revenu
need test volum guidanc stock work discuss
client focu overwhelm revenu rather test volum
continu see sever path test volum ramp guidanc
year view limit visibl uptak nip demand patient-
initi test warrant conserv outlook note test access
guidanc impli growth balanc vs y-o-i growth
forecast impli growth last month
revisit assumpt follow oper updat
prefer network drive consolid unit healthcar recent disclos
plan launch prefer laboratori network pln effect juli
one seven lab network believ structur like pln may effect choke
smaller lab certain specialti lab benefit establish provid like
see industri consolid acceler
refin year forecast also make modest adjust
roughli per test account mix shift toward patient-initi
test carri significantli lower asp test reimburs insur
provid net revenu outlook goe
respect ep forecast goe
respect
diagnost test hereditari cancer
screen famili health plan
variou genet disord provid
predict prognost data
year price histori
analyst certif import disclosur see disclosur
demand diagnost test unlik much healthcar
signific price elast use genom test
expand price sequenc declin best
posit test provid take advantag thesi base
grow economi scale commit drive
cog price lower singl price regardless breadth
genom data deliv breadth test menu
expect model result prefer access payer
relat market share gain upsid street revenu outlook
beyond
nipt test offer limit differenti account low single-
digit percentag sale
medicar reimburs ngs-base test
code unchang level outlin pama
gradual consolid hereditari cancer test market
continu industri remain highli fragment anoth
new collabor pharmaceut compani improv
test access patient suspect harbor rare diseas
addit partnership pharmaceut compani speed
adopt genom screen rare diseas popul
nipt offer meaning revenu contribut base
strength commerci channel
bolt-on acquisit acceler time-to-profit expand
propos medicar fee schedul cut reimburs ngs-
growth reproduct health non-oncolog indic
stall uptak earli adopt translat broad
genet test wide use cancer prenat care
pace adopt cardiovascular diseas immunolog
condit may slower anticip
pt base price-to-sal analysi assum multipl estim revenu million share
outstand discount back one year cost capit
risk reduct reimburs rate ngs-base genet test disrupt laboratori oper san francisco
facil result delay deliveri test result delay launch new product includ nipt neg impact revenu
growth failur fulli integr recent acquisit result reduc product lower return capit inabl
meet undisclos revenu coven relat debt facil
compani report oppenheim co inc estim
genet sell research profit incom profit loss per share continu incom loss loss per share averag common analysisgross invita corp
